TORONTO, March 1, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") today annonced the following:
Restatement of the Engagement of Mr. Peter Hamilton: With respect to the previously announced appointment of Mr. Peter
Hamilton to the position of Executive Vice President of Business
Development of the Company on December 21, 2012, due to a revision in
the Company's restructuring plan, Mr. Hamilton's relationship with the
Company has been changed. Rosseau Consulting Inc., of which Mr.
Hamilton is an employee, has been retained as a consultant to provide
business development services to the Company. As part of such services,
Mr. Hamilton will assist in the provision of such services with the
title of Business Development Consultant. As a result, Mr. Hamilton is
not an executive or employee of the Company and his relationship to
Biosign is that of an independent consultant.
Resignation of Director: Biosign announces the resignation of director Mr. Zoheb Rizvi,
effective immediately. Mr. Rizvi is the General Manager of Markham,
Ontario based Prospec Specialties Inc., and is leaving the board to
devote his time to growing that company. The Board and management wish
to sincerely thank Mr. Rizvi for his service as a director, and wish
him great success in all his future endeavours. Biosign has begun a
selection process to replace Mr. Rizvi on the board. With this
resignation, the Board now consists of independent directors Senator
Alfonse D'Amato and Mr. Jason Meretsky, Chairman John Rizvi, and
Biosign CEO Robert Kaul.
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer
enabled health information products. Key applications include the
noninvasive monitoring of vital signs including blood pressure, pulse
rate and breathing rate, enhanced with web services. The Company's Pulsewave™ medical device technology powers data collection for
clinical decision support, self-care, wellness and disease management,
while it's Healthanywhere™ software suite offers industry-leading
remote patient monitoring solutions. The Company offers a number of
cardiovascular screening programs for consumers under its Heart
Friendly™ brand, including Heart Friendly™ Dentist. For more
information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Biosign Contact Information
Chief Executive Officer
Phone: (416) 218-9800 ext. 201